Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB1 | P05556 | 12/20 | 0.51 |
| ▸ | ITGA4 | P13612 | 10/20 | 0.51 |
| ▸ | ITGB7 | P26010 | 2/20 | 0.51 |
| ▸ | ITGA2 | P17301 | 1/20 | 0.51 |
| ▸ | NOS2 | P35228 | 7/20 | 0.50 |
| ▸ | NOS3 | P29474 | 2/20 | 0.50 |
| ▸ | NOS1 | P29475 | 2/20 | 0.50 |
| ▸ | ITGA5 | P08648 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3819618 | 0.86 | TSHR (0.57) | ITGB1ITGA4ITGB7ITGA2NOS2 | |
| SCHEMBL4928013 | 0.86 | ITGB1 (0.54) | ITGB1ITGA4ITGB7ITGA2NOS2 | |
| SCHEMBL13726463 | 0.86 | ATM (0.59) | ITGB1ITGA4ITGB7ITGA2NOS2 | |
| SCHEMBL8227052 | 0.86 | TSHR (0.57) | ITGB1ITGA4ITGB7ITGA2NOS2 | |
| SCHEMBL5786216 | 0.86 | TSHR (0.57) | ITGB1ITGA4ITGB7ITGA2NOS2 | |
| SCHEMBL297398 | 0.86 | ATM (0.61) | ITGB1ITGA4ITGB7ITGA2NOS2 | |
| SCHEMBL5783896 | 0.86 | ITGA4 (0.57) | ITGB1ITGA4ITGB7 | |
| SCHEMBL1324020 | 0.85 | ITGB1 (0.53) | ITGB1ITGA4ITGB7ITGA2NOS2 | |
| SCHEMBL4067300 | 0.85 | ITGB1 (0.53) | ITGB1ITGA4ITGB7ITGA2NOS2 | |
| SCHEMBL295783 | 0.85 | ITGB1 (0.53) | ITGB1ITGA4ITGB7ITGA2NOS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080045521-A1 | PHENYLALANINE DERIVATIVES | ASTRAZENECA AB (SE) | 2008-02-21 | — | — | US | disclosed |
| US-20080045521-A1 | PHENYLALANINE DERIVATIVES | ASTRAZENECA AB (SE) | 2008-02-21 | — | — | US | disclosed |
| US-20080045521-A1 | PHENYLALANINE DERIVATIVES | ASTRAZENECA AB (SE) | 2008-02-21 | — | — | US | disclosed |
| WO-2007141473-A1 | N-(BENZOYL)-O- [2- (PYRIDIN- 2 -YLAMINO) ETHYL] -L-TYROSINE DERIVATIVES AND RELATED COMPOUNDS AS A5B1 ANTAGONISTS FOR THE TREATMENT OF SOLID TUMORS | ASTRAZENECA AB (SE) | 2007-12-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045521-A1 | PHENYLALANINE DERIVATIVES | ITGB5, ITGB1, ITGA2B | ITGB1 2/4885ITGA4 27/4885ITGB7 28/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.